View:
06-24-2020_CT_ORDER



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION June 24, 2020


ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933


Adverum Biotechnologies, Inc. File No. 333-197133 - CF#35252

image


Adverum Biotechnologies, Inc. (formerly Avalanche Biotechnologies, Inc.) submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on June 30, 2014.


Based on representations by Adverum Biotechnologies, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time period specified:


Exhibit 10.1 through June 24, 2023

Exhibit 10.2 through June 24, 2023

Exhibit 10.3 through June 24, 2023


For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:


Patti J. Dennis

Chief, Office of Disclosure Support